Cytosorbents regained Nasdaq compliance with the $1.00 minimum bid rule after its common stock closed at or above that level. The separate $35 million market-value requirement remains open, with a December 28, 2026 deadline and a possible delisting notice if compliance is not restored.

Key Highlights

  • Nasdaq closed Cytosorbents’ minimum-bid matter on September 22, 2026.
  • The company must restore at least $35 million in Market Value for its listed securities before December 28, 2026.
  • Nasdaq confirmed Cytosorbents restored compliance with the $1.00 minimum bid-price requirement.
  • The bid-price matter was closed under Nasdaq Listing Rule 5550(a)(2).

Nasdaq has confirmed that the company restored compliance with the $1.00 minimum bid-price standard, removing one listing issue while leaving a separate market-value test unresolved.

$1.00 Bid Requirement Closed

The Nasdaq Listing Qualifications Staff notified Cytosorbents (NASDAQ: CTSO) on September 22, 2026, that its common stock had met the required closing bid level through the applicable consecutive trading sessions. The closing bid price was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that the minimum bid-price matter was closed. Cytosorbents had previously received notice that it was below the required bid threshold. The company’s update was signed by Dr. Phillip P. Chan, whose title in the document is Chief Executive Officer, on September 23, 2026.

$35M Listing Test Remains Open

The separate market-value-of-listed-securities requirement calls for at least $35 million. If compliance is not restored before the deadline, Nasdaq will issue written notice that the common stock is subject to delisting, and Cytosorbents may appeal that determination.